TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Group A:~* Males and females aged 18 to 80 yrs~* Diabetes mellitus type 1 or 2~* Haemoglobin level above the treatment threshold level (as described in the drug description)~* Receiving no darbepoetin alfa treatment~* Best Corrected Visual Acuity (BCVA) better than 20/200~* No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation.~Group B:~* Males and females aged 18 to 80 yrs~* Diabetes mellitus type 1 or2~* Anaemia (due to renal failure), haemoglobin level under the treatment threshold level before the initialisation of the therapy (as described in the drug label)~* Starting to receive darbepoetin alfa treatment (darbepoetin alfa, Aranesp, Amgen)~* BCVA better than 20/200~* No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation.~Exclusion Criteria:~* History of retinal disease other than DR~* History of intraocular surgery, including laser treatment in the past 4 month~* A major change in the insulin treatment of the patient in the past 4 month or during the follow up period.~* Inability to communicate in German or English~* Dementia; inability to follow commands~* Epilepsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
- B (Type: None): Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multidimensional Assessment of Dyspnea in Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of asthma confirmed by:~   * A history of symptoms compatible with asthma~  * AND a history of airway obstruction, according to the GINA definition (2017): FEV1/FVC ratio lower than the lower limit of the predicted value at baseline or after a bronchial provocation test~  * AND a variability of airway obstruction defined by at least one of the following criteria:~   oReversibility of airway obstruction after bronchodilators (400 µg of salbutamol): FEV 1 increases by\> 200 mL and\> 12% compared to baseline~  * OR delta peak-flow over the day / average peak-flow averaged over 2 weeks\> 10%~  * OR variability in FEV1 between two visits\> 200 mL and\> 12%~  * OR an increase in FEV1 of\> 200 mL and\> 12% compared to the baseline after 4 weeks of treatment with oral corticosteroids~  * OR a positive methacholine challenge: decrease in FEV1 by more than 20% for a dose \<1600 µg~2. Experience of dyspnea in the past 7 days~3. Age\> 18 years old~4. Social protection affiliation 5. Written informed consent~Exclusion Criteria:~1. Age \<18 years old~2. Active smoker or quitting smoking for less than a year~3. Severe exacerbation or respiratory infection within 4 weeks before inclusion (severe exacerbation is defined by an increase in systemic corticosteroid therapy for at least 3 days or injection of a single dose of delayed corticosteroid, emergency room visit due to asthma (with systemic corticosteroid therapy), or hospitalization due to asthma).~4. Inability to respond to questionnaires for any reason~5. Presence of any pathology other than asthma which may be responsible for dyspnea, in particular cardiovascular or respiratory (ischemic heart disease, heart failure, chronic obstructive pulmonary disease, diffuse interstitial pneumonitis, lung cancer, non-exhaustive list) with the exception of anxiety and hyperventilation syndrome~6. Pregnancy~7. Persons under guardianship~8. Refusal to sign consent or participate in the study~9. No social protection affiliation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- One group (cohort) (Type: None): Asthmatic patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients who aged above 19 and below 75~* Patients with 90\~109mmHg average sitting DBP on baseline~* NYHA class 2\~4~* Patients who agreement with written informed consent~Exclusion Criteria:~* above 110mmHg sitting DBP and/or 180mmHg sitting SBP~* Patients who have difference values that above 20mmHg sitting SBP or 10mmHg sitting DBP in both arms on screening~* Patients who have medical history that secondary hypertension or rule out secondary hypertension~* malignant hypertension~* symptomatic postural hypotension~* right heart failure due to pulmonary disease~* etc.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Candemore tablet (Type: EXPERIMENTAL): Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
- Cozzar tablet (Type: ACTIVE_COMPARATOR): Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm neonates delivered between 24 0/7 and 32 6/7~* Mother carrying a fetus between 24-32 6/7 weeks estimated gestational age~* Written parental consent~Exclusion Criteria:~* Multiple gestation pregnancies (twins or higher order multiples)~* Rh or other antibody sensitization~* Hydrops fetalis~* Known major congenital abnormality~* Suspected abruptio placentae

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Immediate umbilical cord clamping (Type: ACTIVE_COMPARATOR): The umbilical cord will be clamped immediately after delivery.
- Cord milking group (Type: EXPERIMENTAL): The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Delayed Cord Clamping and Use of Oxytocin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy single Term pregnancies.~* Vaginal delivery.~* Informed consent obtained.~* Presence of an investigator~Exclusion Criteria:~* Placenta previa.~* Previous history of Postpartum hemorrhage~* Intrauterine growth restriction .~* Major congenital malformations.~* Eclampsia~* Extraction of blood sample for bank of umbilical cord stem cells.~Elimination criteria:~* Need for immediate assistance of the newborn~* Birth weight less than 2500 g~* Nuchal cord wrapped too tight~* Surgically finished delivery~* Short umbilical cord which might prevent placing the infant on the scale~* Technical difficulties to obtain the weight

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oxytocin inmediately at birth (Type: ACTIVE_COMPARATOR): Intervention: Timing of administration of postpartum Oxytocin. 10 international Units (IU) immediately at birth will be given intravenously (IV) to the mother.
- oxytocin at 3 minutes (Type: EXPERIMENTAL): Intervention: Timing of administration of postpartum Oxytocin. 10 IU IV at 3 minutes immediately after the cord is clamped

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~* Must have evidence of brain metastases by MRI or CT scan~PRIOR CONCURRENT THERAPY:~* Recovered from prior oncologic or major surgery~* Prior resection of all brain metastases or only site of brain metastases allowed provided there is radiologically evaluable intracranial metastases~* No prior cranial irradiation, including stereotactic radiosurgery~* More than 30 days since prior non-approved or investigational drug~* No other concurrent chemotherapy, immunotherapy, hormonal therapy, radiotherapy, surgery, or experimental medications~  * No single brain metastases or oligometastatic disease amenable to surgical resection or radiosurgery~* Relapsed NSCLC with brain metastases allowed~* Not a candidate for double-agent or platinum-based chemotherapy~* No leptomeningeal metastases~* No clinically relevant (defined by physical exam) pleural effusions or ascites that cannot be controlled with drainage or other procedures~Inclusion Criteria:~* Karnofsky performance status 70-100% OR ≥ 70 years of age~* Life expectancy \> 3 months~* Absolute neutrophil count (ANC) \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin ≥ 8 g/dL~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* Creatinine clearance ≥ 45 mL/min~* Able to take vitamins, folic acid, and corticosteroids~Exclusion Criteria:~* Contraindication or intolerance to corticosteroid therapy~* Other malignancies within the past 5 years and disease-free OR prognosis is best defined by the NSCLC in the opinion of the attending physician~* Pregnant or nursing~* Positive pregnancy test~* Fertile patients must use effective contraception~* HIV positive~* Severe hypersensitivity to pemetrexed disodium~* Unable to discontinue NSAIDs for ≥ 5 days~* History of underlying dementia, Parkinson's disease, or Alzheimer's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm Study (Type: OTHER): Single Arm Study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects aged ≥ 18 years at the time of signing the informed consent form (ICF) prior to initiation of any study specific activities/procedures.~* UC diagnosed at least 3 months prior to first dose of investigational product (IP) on Day 1.~* Currently receiving treatment for UC, on a stable dose for at least 2 weeks prior to flexible sigmoidoscopy or colonoscopy, with oral 5-ASA (eg, mesalamine, sulfasalazine) alone or with one of the following oral treatments:~  1. prednisone ≤ 20 mg/day or equivalent or~ 2. beclomethasone ≤ 5 mg/day or~ 3. budesonide or budesonide multi-matrix (MMX) of ≤ 9 mg/day~Exclusion Criteria:~* Prior approved biologic therapy used for the treatment of UC.~* Diagnosis of Crohn's disease, indeterminate colitis, or pouchitis, or presence of bacterial or parasitic infection.~* Tofacitinib, oral cyclosporine, sirolimus or mycophenolate mofetil within 8 weeks of Day 1.~* Azathioprine, or 6-mercaptopurine within 1 day of Day 1.~NOTE: Other Inclusion/Exclusion criteria may apply per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCP Placebo (Type: PLACEBO_COMPARATOR): PCP Placebo for oral administration for 36 weeks
- PCP GB004 480 mg QD (Type: EXPERIMENTAL): PCP GB004 480 mg QD for oral administration for 36 weeks
- PCP GB004 480 mg BID (Type: EXPERIMENTAL): PCP GB004 480 mg BID for oral administration for 36 weeks
- Open-Label Extension (OLE) GB004 480 mg BID (Type: EXPERIMENTAL): OLE GB004 480 mg BID for oral administration for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 to 70 years~* Non-diabetic~* Unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter~* Serum creatinine level within normal range~* Ability to tolerate oral fluids and oral pain medication~* Ability to make informed medical decisions regarding consent~* Willingness to follow up in the ER in two weeks~Exclusion Criteria:~* Adults unable to consent~* Age \<18~* Signs of infection including Temperature \>38º C or Urinalysis with any of the following: Positive Leukocyte Esterase, Positive Nitrates, or White Blood Cell Count \>5/hfp in the setting of a positive urine culture (defined as a single isolated bacterial species population of \>100,000 CFU)~* Patients with chronic pain already undergoing treatment with narcotic medications~* Patients already taking an alpha adrenergic antagonist medication~* Pregnant women~* Prisoners~* No working phone number

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Silodosin (Type: ACTIVE_COMPARATOR): Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
- Tamsulosin (Type: ACTIVE_COMPARATOR): Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Attitudes Toward Physical Activity and Nutrition Intervention During Cancer Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* ≥18 years of age~* Diagnosed with stage I, II or III breast cancer with plans to undergo endocrine and/or chemotherapy treatment (radiation in combination with one or more of these therapies is acceptable)~* Willing to complete up to 4 clinic visits~Exclusion Criteria:~* Have received neoadjuvant therapy for current diagnosis~* Currently receiving adjuvant chemotherapy or other adjuvant therapy that was initiated prior to study enrollment~* History of cancer and neoplastic treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 years or older.~2. Capable of giving informed consent and does provide informed consent.~3. Diagnosis of Meibomian Gland Disease~4. Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative urine pregnancy test is required within 7 days of the participant receiving first dose of study drug along with definite evidence of contraceptive use during the duration of the study. Women of reproductive age should use a method of birth control that is acceptable to the participant and the study doctor. This may include oral contraceptive pills, birth control implants, barrier methods or abstinence. If a participant suspects pregnancy after being enrolled, another pregnancy test will be administered. If the test is positive, the participant will be discontinued from the study immediately.~Exclusion Criteria:~1. Allergic to Brimonidine or any similar products, or excipients of Brimonidine~2. Currently receiving any Brimonidine preparation as a part of glaucoma management~3. Receiving or have received within 30 days any experimental systemic medication.~4. Active ocular infection or ocular allergies.~5. Any history of eyelid surgery or ocular surgery within the past 3 months.~6. Corneal epithelial defect larger than 1 mm2 in either eye.~7. Have active drug/alcohol dependence or abuse history.~8. Vulnerable populations, such as neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brimonidine 0.15% (Type: ACTIVE_COMPARATOR): Brimonidine 0.15% eye drops 2 times a day for 12 weeks
- Brimonidine 0.075% (Type: ACTIVE_COMPARATOR): Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Outpatient men or women aged 50 years or older~2. Must have moderate-to-severe plaque psoriasis for at least 6 months, and for whom a decision to use biologic therapy has been made, with biologic therapy planned to be initiated within the next 4-6 weeks.~3. History of varicella, or having resided in Canada for at least 30 years.~Main Exclusion Criteria:~1. Have received Varicella Zoster Vaccine vaccine or known allergies to the Varicella Zoster Vaccine vaccine or its excipients including neomycin and gelatin~2. Primary and acquired immunodeficiency states due to conditions such as: acute and chronic leukemias, lymphoma, other conditions affecting the bone marrow or lymphatic system, immunosuppression due to HIV/AIDS, cellular immune deficiencies.~3. Current use of non-topical antiviral therapy with known activity against varicella-zoster virus.~4. Exposure to varicella or zoster within 28 days prior to vaccination.~5. Patients who are diagnosed with herpes zoster at the time of the vaccination.~6. Active untreated tuberculosis.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varicella Zoster Vaccine (Type: EXPERIMENTAL): Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
- 0.9% Sodium Chloride (Type: PLACEBO_COMPARATOR): United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.~A single dose will be administered to subjects at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Significance of Pre-interventional Optical Coherence Tomography in Bioresorbable Vascular Scaffold Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 19 years old~* Patients with ischemic heart disease who are considered for coronary revascularization with PCI~* Significant coronary de novo lesion (stenosis \> 70% by quantitative angiographic analysis) treated by single BVS ≤ 28 mm~* Reference vessel diameter of 2.5 to 3.5 mm by operator assessment~Exclusion Criteria:~* Complex lesion morphologies such as aorto-ostial, unprotected left main, chronic total occlusion, graft, thrombosis, and restenosis~* Contraindication or hypersensitivity to anti-platelet agents or contrast media~* Creatinine level ≥ 2.0 mg/dL or ESRD~* Severe hepatic dysfunction (3 times normal reference values)~* Pregnant women or women with potential childbearing~* Inability to understand or read the informed content

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angiography-guidance (Type: ACTIVE_COMPARATOR): None
- OCT-guidance (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy